- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Amylin Pharmaceuticals Inc. (AMLN)
by latest | most commented
-
FDA Helps Investors Look Past Box Warnings
-
How Bad Is Sanofi's Safety Scare?
-
Friday's Options Recap
-
ADA Meeting 2009: Novel Diabetes Therapies Presented
-
Amylin, Biogen Idec Stand to Benefit from Icahn Board Victories
-
Amylin Update Post ADA Meeting
-
Amylin: Icahn, Eastbourne Celebrate Disposal of Chairman
-
Shareholder Activists Week in Review: Winners and Losers
-
Key Amylin Catalyst Expected Wednesday
-
What's in Store for Amylin and Biogen Idec's Shareholder Meetings?
-
Saks Incorporated: Peter Schoenfeld Calls for Changes
-
Smart Money Moves in Q109
-
Michael Mauer Leaves Citi for Icahn
-
What Amylin's Established Drugs Are Worth Alone
-
Amylin: I'm Not Taking Sides
-
Amylin: Icahn's Proxy Damning for Management
-
Who Will Win the Amylin Battle?
-
Early Filing for Byetta: Will It Become a Blockbuster?
-
FDA Calendar Updates: Amylin, Alkermes, Eli Lilly, Cell Therapeutics
-
Amylin: A Discounted Option on Byetta's Outcome
-
Poison Puts: Amylin's Poison Pill du Jour
-
CNBC's Fast Money - What to Do About Yahoo? (4/20/09)
-
The ABCs of Lilly: Amylin, Byetta & Carl
-
Wall Street Breakfast: Must-Know News
-
Amylin's Pullback Is Unjustified
-
Which Diabetes Drugs Will Win Out?
-
Farallon Capital's Q408: Betting on MasterCard
-
Wednesday's Options Recap
-
Amylin Shares Find Support, But Upside Still Limited
-
Tudor Investment Takes New Positions in Financials, Among Others
-
Where Might Genentech Investors Redeploy $47B?
-
Biotech Is Now the Place to Be for Big Pharma
-
Merck's Jumpin' Januvia Gets a Reprieve
-
Carl Icahn Portfolio Update: Q4 2008
-
Wall Street Breakfast: Must-Know News
-
Icahn Boosts Stake in Amylin: Look for a Future Sale
-
Wall Street Breakfast: Must-Know News
-
Stocks Affected by FDA Calendar of Expected Decision Dates
-
Hedge Fund Portfolio Tracking: Citadel Investment Group (Ken Griffin), Q3 2008
-
Fast Money Recap - Bullish on Biotech (1/5/09)
-
Hedge Fund Tracking: Farallon Capital Management (Thomas Steyer), Q3 2008